Every Form 4 that The Chemours Company (CC) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CC filings page.
Chemours Co Chief Accounting Officer David Will reported a Form 4 transaction involving 2,426 shares of common stock on August 12, 2026. These shares were automatically withheld to satisfy tax obligations upon vesting of restricted stock units and related dividend equivalent units, at a value of $15.24 per share. The filing specifies that no shares were sold in the open market. Following this tax-withholding disposition, Will’s holdings, including directly owned shares, restricted stock units, and dividend equivalent units, total 30,868.097 shares.
Chemours Co executive Gerardo Familiar Calderon, President of Advanced Performance Materials, purchased 1,935 shares of Common Stock on August 12, 2026 at $15.53 per share in an open-market or private transaction. Following this transaction, his directly owned and equity-based holdings total 58,547.3746 shares, which include directly owned shares, restricted stock units, and dividend equivalent units, and reflect an adjustment correcting an administrative error in prior reports.
Chemours Co Chief Executive Officer and director Denise Dignam purchased 3,378 shares of Chemours common stock on 2026-08-11 at $14.95 per share in an open-market transaction. Following this trade, she directly owns a total of 339,916.3423 shares, which includes directly owned shares, restricted stock units and dividend equivalent units, with the total adjusted to correct an administrative error in prior reports.
Chemours Co executive Michael Robert Foley, President of Titanium Technologies, purchased 1,934.2313 shares of common stock on August 7, 2026 in an open-market transaction at a weighted average price of $15.51 per share, with individual trade prices ranging from $15.51 to $15.54.
Chemours Co director Alister Cowan purchased 13,000 shares of Chemours common stock on August 7, 2026 in an open-market transaction at a weighted average price of $15.62 per share, with individual trade prices ranging from $15.58 to $15.62. Following this purchase, Cowan’s directly owned holdings, including restricted stock units and dividend equivalent units, total 56,988.0387 shares.
Chemours Co director Mary B. Cranston purchased 6,000 shares of Chemours common stock in an open-market transaction on 2026-08-07 at a price of $15.825 per share. Following this purchase, she reports beneficial ownership of 113,140.9469 shares, which includes directly owned shares, restricted stock units, and dividend equivalent units.
Chemours Co executive Joseph T. Martinko, President of Thermal & Specialized Solutions, reported a purchase of 1,939.8014 shares of common stock on August 7, 2026 at $15.47 per share in an open-market or private transaction. Following this transaction, his reported direct holdings total 55,431.4012 shares, which include directly owned shares, restricted stock units, and dividend equivalent units.
Chemours Co Chief Financial Officer Shane Hostetter purchased common stock in a personal transaction. On 2026-08-06, he bought 3,350 shares of Chemours common stock at $14.94 per share. Following this purchase, he directly and beneficially owned a total of 102,697.7058 shares, which includes directly owned shares, restricted stock units, and dividend equivalent units.
Chemours Co Chief Financial Officer Shane Hostetter reported a disposition of 3,087 shares of common stock on 2026-08-06. According to the disclosure, these shares were automatically withheld to satisfy tax obligations upon vesting of restricted stock units and related dividend equivalent units, and no shares were sold. Following this tax-withholding transaction, Hostetter directly holds a total of 99,347.7058 shares, including common shares, restricted stock units, and dividend equivalent units.
Chemours Co reports that President, Advanced Performance Materials, Familiar Calderon Gerardo had 943 shares of common stock automatically withheld on August 1, 2026 to satisfy tax obligations on vesting restricted stock units and dividend equivalent units.
No shares were sold in the market, and holdings after the withholding were 58,498.8899 shares, including directly owned shares, restricted stock units and dividend equivalent units.
Chemours Co executive Joseph T. Martinko, President, Thermal & Specialized Solutions, had 663 shares of common stock automatically withheld on 2026-08-01 at $16.61 per share to satisfy tax obligations on vesting restricted stock units and dividend equivalent units. Footnotes state this was a tax-withholding disposition and that no shares were sold. After this event, Martinko holds a total of 54,818.5559 shares, including directly owned shares, restricted stock units and dividend equivalent units.
Chemours Co director and Chief Executive Officer Denise Dignam reported a tax-withholding disposition of 477 shares of common stock on August 1, 2026 at $16.61 per share. Shares were automatically withheld to satisfy tax obligations on vesting restricted stock units and dividend equivalent units; no shares were sold. Following this withholding, she reported 337,492.9016 shares held directly, including restricted stock units and dividend equivalent units.
Chemours Co reported that SVP, GC & Corp. Secretary Kristine M. Wellman had 391 shares of common stock automatically withheld on August 1, 2026 at $16.61 per share to satisfy tax obligations on vesting restricted stock units and dividend equivalent units. Footnotes state that no shares were sold, and her direct holdings, including shares, restricted stock units and dividend equivalent units, total 74,418.8998 shares after this transaction.
Chemours Co director Courtney Mather received a grant of deferred stock units as part of board compensation. On this date, Mather acquired 1,401 deferred stock units, each economically equivalent to one share of Chemours common stock, at a reference value of $20.52 per unit.
The award increases Mather’s directly held deferred stock units to a total of 8,983.8481 units, including dividend equivalent units. These deferred stock units become payable in shares of common stock in the first month after Mather’s termination of service as a director, so they function as long-term, non-cash compensation rather than an open-market purchase.
CRANSTON MARY B reported acquisition or exercise transactions in this Form 4 filing.
Chemours Co director Mary B. Cranston received an equity grant of 7,182 shares of common stock on May 6. The award was granted at no cash cost to her, reflecting stock-based compensation rather than an open-market purchase.
After this grant and an adjustment to correct an administrative error in prior filings, her direct and deferred holdings now total 106,830.0129 shares, including deferred stock units and related dividend equivalent units.
Chemours director Leslie M. Turner received a grant of 7,182 stock units of Chemours common stock on May 6, 2026. The units were awarded at no cash cost and increase Turner’s direct holdings to 24,603.3891 stock units.
According to the footnotes, these stock units, including deferred stock units and dividend equivalent units, will convert one-for-one into Chemours common stock when Turner separates from service on the Board. This reflects routine equity-based board compensation rather than an open-market purchase.
Chemours Co director Pamela Fletcher received a grant of 7,182 shares of Common Stock on May 6, 2026, as a stock award. The shares were awarded at a price of $0.00 per share as compensation, not an open-market purchase.
The award represents stock units that will convert one-for-one into Chemours common stock upon her separation from service on the Board and includes deferred stock units and dividend equivalent units. After this grant, Fletcher directly holds a total of 32,382.9997 shares of Chemours common stock.
Chemours director Alister Cowan reported a grant of 7,182 stock units of Chemours common stock. The units were acquired at a stated price of $0.00 per share as a compensation award. Following this grant, Cowan directly holds 43,881.0397 shares or stock units in total.
The granted stock units, including deferred stock units and dividend equivalent units, will convert one-for-one into Chemours common stock when Cowan separates from service on the Board.
Chemours director Courtney Mather received a grant of 7,182 stock units of Chemours common stock on May 6, 2026. These stock units will convert one-for-one into Chemours common shares upon separation from service on the Board and include deferred and dividend equivalent units. Following this award, Mather holds a total of 21,642.7173 stock units directly.
Chemours Co director Erin N. Kane received a grant of 7,182 Chemours common stock units as board compensation. The award was recorded at a price of $0.00 per unit and increases Kane’s directly held stock units to 74,062.9086.
The footnotes explain these are stock units that will convert one-for-one into Chemours common shares when Kane separates from service on the Board, and that the total includes both deferred stock units and related dividend equivalent units. This is a non-cash, routine equity award rather than an open-market purchase.
Chemours Co director Livingston Satterthwaite received an equity award of 7,182 stock units of Chemours common stock as board compensation. The units were granted at no cash cost to the director and will convert one-for-one into Chemours common shares upon separation from board service.
The award includes deferred stock units and related dividend equivalent units, increasing Satterthwaite’s directly held balance to 30,807.855 shares and stock units combined after this transaction.
Chemours Co director Sean D. Keohane received a grant of 7,182 stock units of Chemours common stock at a price of $0.00 per unit. These stock units will convert one-for-one into Chemours common stock when he separates from service on the Board.
The grant includes deferred stock units and related dividend equivalent units. Following this award, Keohane holds a total of 72,555.1777 shares and stock units of Chemours common stock directly.
Chemours director Joseph Daniel Kava received a grant of 7,182 stock units of Chemours common stock. The units were awarded at a price of $0.00 per share as board compensation. Following this award, Kava directly holds a total of 24,603.3891 stock units. According to the disclosure, these stock units will convert one-for-one into Chemours common stock when Kava separates from service on the Board, and the total includes both deferred stock units and related dividend equivalent units.
Brokaw George R reported acquisition or exercise transactions in this Form 4 filing.
Director George R. Brokaw of Chemours Co received an award of 7,182 shares of Common Stock on May 6, 2026. The shares were granted at $0.00 per share as compensation rather than a market purchase. Following this grant, his direct holdings, including deferred stock units and dividend equivalent units, total 21,642.7173 shares of Chemours common stock.
MATHER COURTNEY reported acquisition or exercise transactions in this Form 4 filing.
Chemours director Courtney Mather received a routine equity grant in the form of deferred stock units. On this Form 4, Mather was awarded 1,305 deferred stock units at an indicated value of $22.03 per unit, each equivalent to one share of Chemours common stock.
The deferred stock units, including associated dividend equivalent units, will become payable in the first month after Mather’s termination of service as a director. Following this grant, Mather holds a total of 7,552.3528 deferred stock units, representing deferred, not currently exercisable, equity-based compensation.
Chemours senior vice president Kristine M. Wellman reported equity compensation and related tax withholding transactions in company common stock. She received a grant of 25,708 restricted stock units, which are scheduled to vest in three equal annual installments beginning on March 1, 2027. To cover tax obligations from previously vesting RSUs and dividend equivalent units, 3,359 shares were automatically withheld at a price of $18.24 per share, and the disclosure states that no shares were sold in the market. After these changes, she reports direct ownership of 73,750.6057 shares, RSUs, and dividend equivalent units in total.
Chemours executive Gerardo Familiar Calderon reported equity compensation changes involving company common stock. He received a grant of 25,708 shares of common stock at a price of $0.0000 per share as a grant, award, or other acquisition, structured as restricted stock units and related dividend equivalent units.
Separately, 2,635 shares were automatically withheld at $18.24 per share to satisfy tax obligations upon vesting of existing restricted stock units; footnotes state that no shares were sold and the transaction is exempt under Rule 16b-3. The new RSU award is scheduled to vest in three equal annual installments beginning on March 1, 2027, and the reported holdings include directly owned shares, RSUs, and dividend equivalent units.
Chemours Chief Executive Officer Denise Dignam reported equity compensation changes. She received a grant of 169,538 shares of common stock at $0.00 per share, in the form of restricted stock units scheduled to vest in three equal annual installments beginning on March 1, 2027. To satisfy tax obligations on vesting RSUs and related dividend equivalent units, 22,220 shares were automatically withheld at $18.24 per share; the company notes no shares were sold in the market. Following these transactions, she directly holds 335,313.8721 shares, including RSUs and dividend equivalent units.
Chemours Co reported that officer Michael Robert Foley acquired two grants of common stock in the form of restricted stock units. One award covers 25,013 RSUs that vest in three equal annual installments beginning on March 1, 2027, and another covers 50,027 RSUs scheduled to vest on March 1, 2029. Following these awards, Foley directly holds or is credited with 78,540 Chemours equity units, including directly owned shares, RSUs and related dividend equivalent units.
Chemours officer Joseph T. Martinko reported two stock transactions involving company common shares. On March 2, 2026, he acquired 28,488 shares at $0.00 per share through a grant classified as a grant, award, or other acquisition. On March 1, 2026, 2,789 shares at $18.24 per share were automatically withheld to cover tax obligations tied to vesting restricted stock units and related dividend equivalent units, and the footnote clarifies that no shares were sold on the market. After these transactions, his directly held and unit-based interests total 53,889.1669 shares, including common stock, restricted stock units, and dividend equivalent units. The RSU grant is scheduled to vest in three equal annual installments beginning on March 1, 2027, providing a staged equity-based compensation stream over time.
Chemours Chief Financial Officer Shane Hostetter reported equity compensation and related tax withholding transactions in company common stock. On March 2, he acquired 47,387 shares through a grant or award at a stated price of $0.0000 per share, increasing his directly owned and unit-based holdings to 101,857.1999 shares. A related footnote states this restricted stock unit (RSU) award is scheduled to vest in three equal annual installments beginning on March 1, 2027. On March 1, 3,232 shares at $18.2400 per share were automatically withheld to satisfy tax obligations on vesting RSUs and dividend equivalent units, with the filing clarifying that no shares were sold. Following the tax-withholding disposition, his directly held total was 54,470.1999 shares, which a footnote explains includes directly owned shares, RSUs and dividend equivalent units.
Chemours Co Chief Accounting Officer David Will reported an equity award and a related tax withholding transaction. He received a grant covering 8,337 shares of common stock at no cost, structured as an RSU award scheduled to vest in three equal annual installments beginning on March 1, 2027. In a separate transaction, 699 shares were automatically withheld at $18.24 per share to satisfy tax obligations on vesting restricted stock units and dividend equivalent units; the footnote states that no shares were sold in the market. Following these transactions, his directly owned holdings, including RSUs and dividend equivalent units, total 33,083.5415 shares.
Chemours Co senior vice president and general counsel Kristine M. Wellman reported routine equity compensation transactions in company common stock. She acquired 1,781 shares at no cost through performance stock units granted under the Long Term Incentive Plan, which vested after the compensation committee certified performance conditions were met.
To cover related tax obligations on vesting restricted stock units and dividend equivalent units, 675 shares were automatically withheld at a price of $18.41 per share; the footnotes state no shares were sold on the market. After these transactions and an adjustment correcting a prior administrative error, her directly owned, restricted stock unit, and dividend equivalent unit holdings total 51,401.6057 shares.
Chemours Co Chief Executive Officer Denise Dignam received 2,261 shares of common stock as a performance-based stock award tied to 2023 compensation, issued at no cash cost to her after performance conditions were certified. To cover taxes on vesting, 742 shares were automatically withheld at $18.4100 per share, and the footnotes state that no shares were sold. Following these transactions and an adjustment for a prior administrative error, her directly owned and related holdings total 187,995.8721 shares, including restricted stock units and dividend equivalent units.
Chemours Co director reports new deferred stock units. A member of the board received 1,298 deferred stock units on 12/31/2025. Each unit is the economic equivalent of one share of Chemours common stock at a reference price of $11.79. These deferred stock units, together with related dividend equivalent units, will be paid in the second calendar year after the director’s service on the board ends. Following this grant, the director beneficially owns 4,615.309 derivative securities in the form of deferred stock units, held directly.
Chemours Company director reports deferred stock units grant
A director of Chemours Company reported receiving 2,226 deferred stock units on 12/31/2025. Each deferred stock unit is the economic equivalent of one share of Chemours common stock and becomes payable in the first month after the director’s termination of service. The transaction price is listed as $11.79 per unit. Following this grant, the reporting person beneficially owns a total of 6,216.3946 deferred stock units, which include both deferred stock units and related dividend equivalent units, all held in direct ownership.
Chemours director Satterthwaite Livingston received 966 deferred stock units on 09/30/2025, each equal to one share of Chemours common stock and recorded at an acquisition price of $15.84 per unit. After the transaction the reporting person beneficially owns 3,280.0507 shares (direct). The deferred stock units become payable beginning the second calendar year after the reporting person ceases service as a director, so these units represent compensation that vests for payout on termination rather than immediate cash or share delivery. The Form 4 was signed by an attorney-in-fact on 10/02/2025 and identifies the reporting person as a director of Chemours (ticker: CC).
Courtney Mather, a director of Chemours Co (CC), reported acquisition of deferred stock units tied to common shares on 09/30/2025. The Form 4 shows 1,657 deferred stock units were acquired at a reported unit value of $15.84 each. Each deferred stock unit is the economic equivalent of one share of common stock and becomes payable after the director leaves board service. After the reported transaction the filing indicates the reporting person beneficially owns 3,960.9731 shares in a direct ownership form.